# Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

> **NCT05555732** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 1170 (estimated)

## Conditions studied

- Metastatic Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Datopotamab Deruxtecan
- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05555732
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-11
- **Primary completion:** 2029-05-11
- **Final completion:** 2029-05-11
- **Target enrollment:** 1170 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05555732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05555732, "Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05555732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*